Drug development in anaesthesia: industrial perspective

Area of Science:

• Anesthesiology
• Pharmacology
• Drug Development

Background:

• The field of anesthesia is continuously evolving with new therapeutic agents.
• Understanding the mechanisms of action for existing anesthetics is crucial for developing novel drugs.
• Despite advances, there remains a need for improved sedative, hypnotic, and analgesic agents.

Purpose of the Study:

• To review and summarize novel drugs currently in development within the field of anesthesia.
• To identify emerging trends and potential therapeutic targets in anesthetic drug discovery.
• To assess the current landscape of drug development for sedatives, hypnotics, and neuromuscular blockers.

Main Methods:

• Literature review of recent publications and clinical trial data.
• Analysis of drug development pipelines for anesthetic agents.
• Identification of novel drug candidates and their proposed mechanisms of action.

Main Results:

• Several novel drug candidates are in development, including propofol prodrugs (e.g., Aquavan) and new 'soft-drug' sedatives/hypnotics (e.g., CNS-7259X, TD-4756).
• Sugammadex represents a novel approach for reversing steroidal neuromuscular blockers.
• Significant activity is noted in novel analgesics, but less so for sedatives, hypnotics, and neuromuscular blockers.
• New targets, such as the beta3-subunit of GABA-A receptors, show promise for developing agents with improved safety profiles.

Conclusions:

• The perception of low need for new anesthesia drugs in the industry may be hindering development.
• Anesthesiologists must effectively communicate their unmet needs to stimulate further drug discovery.
• Targeting specific receptor subunits, like those in GABA-A, offers potential for safer and more effective anesthetic agents.